<DOC>
	<DOCNO>NCT02673814</DOCNO>
	<brief_summary>The primary purpose research study see whether add bavituximab ( investigational drug ) durvalumab improve result treatment non-small-cell lung cancer .</brief_summary>
	<brief_title>Phase 2 Trial Durvalumab With Without Bavituximab Patients With Previously Treated Metastatic Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed Written Informed Consent Male female least 18 year age Histologically cytologically document NSCLC ( Nonsmallcell lung carcinoma ) present Stage IV disease ( accord American Joint Committee Cancer Staging Manual [ 7th edition ] ) recurrent disease progressive disease follow multimodal therapy ( radiation therapy , surgical resection , definitive chemoradiation therapy locally advanced disease ) Disease recurrence progression one prior platinumbased doublet chemotherapy treatment advance metastatic disease Measurable disease crosssectional imaging per RECIST 1.1 Eastern Cooperative Oncology Group performance status 0 1 Tumor tissue ( archival recent tumor biopsy ) must available biomarker evaluation Adequate hematologic function ( absolute neutrophil count ≥1500 cells/µL ; hemoglobin ≥9 g/dL ; platelet ≥100,000/µL ) . Serum creatinine CL &gt; 40 mL/min CockcroftGault formula 24hour urine collection determination creatinine clearance Adequate hepatic function ( serum bilirubin ≤1.5 × ULN , serum albumin level ≥3.0 g/dL , alanine aminotransferase [ ALT ] ≤2.5 × ULN , aspartate aminotransferase [ AST ] ≤2.5 × ULN ) Female patient must either nonreproductive potential must negative serum pregnancy test upon study entry All patient reproductive potential ( ie , surgically sterile postmenopausal ) must agree use highly effective method contraception 90 day end study treatment Known history bleed diathesis coagulopathy ( von Willebrand disease hemophilia ) Tumors invade large blood vessel , opinion Investigator , put patient risk major hemorrhage Clinically significant bleeding , gross hematuria , gastrointestinal bleeding , hemoptysis within 6 month screen , unless cause identify adequately treat ( eg , cystitis , ulcer ) Thromboembolic event ( eg , deep vein thrombosis , pulmonary embolism , arterial thrombosis ) within 6 month screen Symptomatic coronary artery disease , cerebrovascular accident , transient ischemic attack , myocardial infarction , arterial embolism , unstable angina pectoris within 6 month prior screen QT interval use Fridericia 's Correction ( QTc ) &gt; 500 m Symptomatic clinically active brain metastasis . Patients eligible brain metastasis adequately treat . Patients must either corticosteroids stable decrease dose ≤10 mg daily prednisone ( equivalent ) . Patients symptomatic interstitial lung disease inflammatory pneumonitis may interfere detection management suspect drugrelated pulmonary toxicity Other active malignancy require concurrent intervention . Acute toxicity attribute prior anticancer therapy alopecia fatigue must resolve Grade 1 baseline administration study drug Active prior document autoimmune disease within past 2 year Current prior use immunosuppressive medication within 28 day first dose durvalumab , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid Active prior document inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis ) History primary immunodeficiency History allogeneic organ transplant Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses include subject know evidence acute chronic hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability patient give write informed consent Previous clinical diagnosis tuberculosis History hypersensitivity excipients bavituximab durvalumab include polysorbate80containing infusion . Serious nonhealing wound , include wound heal secondary intention Major surgery within 4 week prior Cycle 1 Day 1 ( C1D1 ) Receipt live attenuate vaccination within 30 day prior study entry within 30 day receive durvalumab Prior therapy PD1 PDL1 inhibitor , include durvalumab . Prior therapy bavituximab . Investigational therapy within 28 day prior C1D1 . Patient condition situation , Investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>